{"id":35867,"date":"2026-08-18T15:25:00","date_gmt":"2026-08-18T13:25:00","guid":{"rendered":"https:\/\/askme.it\/insights\/kol-management-2026-three-generations-in-ten-years\/"},"modified":"2026-05-28T17:54:51","modified_gmt":"2026-05-28T15:54:51","slug":"kol-management-2026-three-generations-in-ten-years","status":"publish","type":"insights","link":"https:\/\/askme.it\/en\/insights\/kol-management-2026-three-generations-in-ten-years\/","title":{"rendered":"KOL management 2026: three generations in ten years"},"content":{"rendered":"
\n

Market estimates on KOL Management Software converge on a value of around 462 million dollars in 2024 with a projection to 1.19 billion by 2033, an annual compound growth of 10.9% according to MarketIntelo. The Medical Affairs KOL Engagement Analytics segment, defined more broadly, is estimated by Custom Market Insights at 0.82 billion in 2025 with a projection to 3.61 billion in 2034 and a compound rate of 17.8%. The difference between the two figures depends on what is included in the definition \u2014 only software platform or platform plus analytics plus services plus engagement budget \u2014 but the sense is consistent: KOL management is one of the pharma CRM segments with the highest growth rate, and the three generations of technology that have overlapped in the last ten years do not replace one another but stratify.<\/p>\n

The first generation is the traditional KOL model, based on three tiers \u2014 national, regional, local \u2014 built through advisory boards and references from representatives, with engagement measured in number of meetings and number of publications. The second generation is the Digital Opinion Leader (DOL), which emerged after 2015 as a social-native variant of the classic KOL, identified through peer-to-peer impact metrics and not simple follower count. The third generation, operational since 2024-2025, is the AI agent that summarizes in a one-page brief the state of a KOL combining PubMed publications, participation in clinical trials, presence at congresses, payment trail, social activity and media coverage. The three generations coexist within the same KOL program of a large pharma in 2026.<\/p>\n<\/section>\n

\n

The end of the static tier model<\/h2>\n

The classic three-tier model \u2014 Tier 1, 2 and 3 for influence \u2014 is still the most widespread presentation mode in medical affairs department reports, but its internal construction has stopped being static. New-generation platforms ground the classification on network analysis applied to public data: who cites whom in scientific publications, who co-authors with whom the trials registered on ClinicalTrials.gov and the EU Clinical Trials Register, who speaks at which congresses, who reacts to whom on social peer networks such as Doximity or Sermo. The result is an influence map that is graphic and dynamic, in which the tier has become the condensed presentation of an underlying network structure.<\/p>\n

Within3 is probably the purest example of this approach: in 2025 it acquired rMark Bio for discovery AI and Voxx Analytics for network analysis, and in March 2026 it launched its Dataverse ecosystem. The platform grounds KOL identification on what it calls Disease Community Landscape, a map of communities of practice by therapeutic area built through digital behaviors \u2014 posts, votes, comments, interactions \u2014 more than through traditional scientometric scoring. H1, after the 2025 acquisitions of Ribbon Health, Faculty Opinions and Carevoyance, declares coverage of 10 million HCPs and 12 million profiles in its HCP Universe, and in its marketing claims a 275% improvement in KOL identification compared to traditional methods \u2014 a figure that remains a non-externally-audited vendor claim but that reflects the directional advancement of the sector.<\/p>\n<\/section>\n

\n

The platforms: Veeva Link, IQVIA OneKey, H1, Within3<\/h2>\n

Veeva Link Key People aggregates more than three million KOL profiles in over 85 countries, sourcing from more than 250 thousand public sources that include PubMed, congress sites, professional social networks, clinical trial registries, news, company disclosure systems. Each profile includes publications, trials, congress participations, clinical guidelines, grants received, payments registered, social posts. Veeva integrates Link with Vault CRM and OpenData to build a KOL record that lives inside the operational workflow of the sales force and medical affairs without requiring a second system.<\/p>\n

IQVIA OneKey, already cited as reference data in the broader pharma CRM, is the canonical base of most European KOL programs, with 25 million HCPs in 118 countries, 250 attributes per record and 1.5 million updates per month at the global level. The IQVIA-Veeva partnership formalized in 2025 allows OneKey to feed Veeva Network and Veeva AI, reducing the duplication of reference data between IQVIA reference and Veeva operational. H1 is probably the most aggressive platform on acquisitions and on AI in this category. Within3 is the most focused on network analysis. Definitive Healthcare is the main reference in the United States for the DOL dimension. The choices between these platforms depend less on data quality \u2014 which has stopped being the main differentiator \u2014 and more on integration with the rest of the pharma stack and on local compliance constraints.<\/p>\n<\/section>\n

\n

AI in KOL: NLP plus entity resolution on public data<\/h2>\n

The vendor narrative of 2025-2026 has shifted the KOL discourse toward the term “AI”, but to a large extent what platforms do is a very specific combination of consolidated technologies. NLP to extract structured information from PubMed publications, articles on MedRxiv and BioRxiv, congress proceedings, trial registries. Entity resolution to reconcile the same physician cited in different sources with different spellings and different roles. Graph databases to model the network of co-authorship, co-presentation and co-citation. Only downstream of these three layers do the large language models arrive \u2014 Claude, GPT-4, Gemini \u2014 for the generation of the brief readable by medical affairs.<\/p>\n

The added value of LLMs in 2026 KOL management is not in identification, which remains an entity resolution problem solved with classical techniques, but in synthesis: the KOL brief that required two hours of work from an MSL is now produced in thirty seconds by a model that has read the physician’s last twenty publications, the agenda of the last congress where they spoke, the clinical guidelines where they are cited and their social activity over the last six months. Anthropic launched Claude for Life Sciences in October 2025 and Claude for Healthcare at JP Morgan Healthcare 2026; PwC announced an alliance with Anthropic for enterprise agentic; Bristol Myers Squibb signed an enterprise agreement dedicated to commercial. The agent-generated KOL brief is one of the first production-ready use cases of this transition.<\/p>\n<\/section>\n

\n

Italy: regional KOLs count more than national ones<\/h2>\n

The Italian KOL model has a specificity that global platforms capture only partially. The network of regional opinion leaders in oncology, cardiology, neurology, diabetology and other high-specialization therapeutic areas is dense and operationally much more relevant than what global scoring systems suggest. The head of department of a large Italian regional hospital in a therapeutic area with high prescription intensity can have an impact on clinical practice in their own territory greater than that of a national KOL with a more visible academic profile. Network analysis platforms that integrate Italian publications, participation in national congresses Sicup, Aiom, Anmco, and presence in regional drug committees manage to surface these profiles. Platforms that work only on PubMed and international congresses miss them.<\/p>\n

For Italian pharmaceutical companies the operational message is that an effective KOL program in 2026 cannot be founded only on the national tier: it must include a regional map built on Italian sources, integrated with global platforms for the international dimension. The Italian system integrator who knows the sources \u2014 Aifa, regional drug committees, Italian scientific societies, the Aimar registries \u2014 produces a KOL asset that global platforms alone cannot produce.<\/p>\n<\/section>\n

\n

The ethical constraint: Farmindustria 2025 and Sanita Trasparente as design constraint<\/h2>\n

The constraint that configures Italian and European KOL management is not technological, it is regulatory. The Farmindustria Code of Conduct, latest revision February 21, 2025, prohibits promotional purposes in the relationship with the HCP, requires that any information on product be provided on unsolicited request, requires annual disclosure of research grants by 30 June and imposes traceable procedures for advisory boards, congress sponsorships and fees for professional services. The EFPIA Code, on the European front, requires the consolidated publication of transfers of value between 20 and 30 June of each year. Sanita Trasparente, operational since 2025, requires public disclosure to the Ministry of Health of every transfer above the thresholds of 100 euros per event and 1,000 euros per year toward a single HCP.<\/p>\n

Translated into KOL program design: every interaction must be classified as promotional or non-promotional, every grant must be tracked, every payment must be disclosed. An AI-driven KOL platform that explicitly optimizes for “prescription advocacy” sits in an area of reputational and disciplinary risk incompatible with the Italian and European framework. The correct design constraint for 2026 is one in which KOL management is a tool for scientific advancement and bidirectional exchange of clinical evidence \u2014 KOLs inform planning, receive early access to data, participate in structured advisory boards \u2014 and AI orchestration accelerates identification, synthesis and traceability of interactions, without shifting the declared purpose of the program. The ethical limit is not a brake on technology. It is the most important technical specification that the system must respect.<\/p>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

Veeva Link aggregates three million KOL profiles from 250 thousand public sources, IQVIA OneKey tracks 25 million of them as HCPs, H1 has brought them to twelve million after the 2025 acquisitions. KOL management has shifted from three-tier segmentation toward network analysis, but in Italy the Farmindustria Code of Conduct and Sanita Trasparente constrain every interaction: the design constraint is ethical, not technical.<\/p>\n","protected":false},"featured_media":35869,"menu_order":0,"template":"","insights_category":[968],"insights_tags":[901,900,904,903,902],"class_list":["post-35867","insights","type-insights","status-publish","has-post-thumbnail","hentry","insights_category-ai-and-pharma","insights_tags-digital-opinion-leader","insights_tags-kol-management","insights_tags-medical-affairs","insights_tags-network-analysis","insights_tags-veeva-link"],"acf":[],"_links":{"self":[{"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights\/35867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights"}],"about":[{"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/types\/insights"}],"version-history":[{"count":1,"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights\/35867\/revisions"}],"predecessor-version":[{"id":35868,"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights\/35867\/revisions\/35868"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/media\/35869"}],"wp:attachment":[{"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/media?parent=35867"}],"wp:term":[{"taxonomy":"insights_category","embeddable":true,"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights_category?post=35867"},{"taxonomy":"insights_tags","embeddable":true,"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights_tags?post=35867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}